Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 October 2020Website:
http://ateapharma.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:21:07 GMTDividend
Analysts recommendations
Institutional Ownership
AVIR Latest News
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET with company representatives Jonae Barnes, Jean-Pierre Sommadossi, Arantxa Horga, Janet Hammond, John Vavricka, and Andrea Corcoran. Conference call participants include Maxwell Skor, Jonathan Miller, Tim Lugo, and Rosa Chen. The operator welcomes everyone to the call and notes that all participants are currently in listen-only mode.
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Andrea Corcoran - CFO, EVP, Legal & Secretary John Vavricka - Chief Commercial Officer Conference Call Participants Eric Joseph - JPMorgan Chase & Co. Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Rosa Chen - Leerink Partners John Boyle - William Blair & Company Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call.
What type of business is Atea Pharmaceuticals?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
What sector is Atea Pharmaceuticals in?
Atea Pharmaceuticals is in the Healthcare sector
What industry is Atea Pharmaceuticals in?
Atea Pharmaceuticals is in the Biotechnology industry
What country is Atea Pharmaceuticals from?
Atea Pharmaceuticals is headquartered in United States
When did Atea Pharmaceuticals go public?
Atea Pharmaceuticals initial public offering (IPO) was on 30 October 2020
What is Atea Pharmaceuticals website?
https://ateapharma.com
Is Atea Pharmaceuticals in the S&P 500?
No, Atea Pharmaceuticals is not included in the S&P 500 index
Is Atea Pharmaceuticals in the NASDAQ 100?
No, Atea Pharmaceuticals is not included in the NASDAQ 100 index
Is Atea Pharmaceuticals in the Dow Jones?
No, Atea Pharmaceuticals is not included in the Dow Jones index
When was Atea Pharmaceuticals the previous earnings report?
No data
When does Atea Pharmaceuticals earnings report?
The next expected earnings date for Atea Pharmaceuticals is 08 November 2024